

## FYARRO® (sirolimus protein-bound particles for injectable suspension) (albumin-bound) Medication Precertification Request

Aetna Precertification Notification Phone: <u>1-866-752-7021</u> (TTY: <u>711</u>)

FAX: <u>1-888-267-3277</u>

For Medicare Advantage Part B: Please Use Medicare Request Form

		Page 1 of 1	completed and legible f		review )				
Dlagge indicate:	☐ Start of treatmen		-	or preserancation i	oview.)				
riease illuicate.			last treatment	1 1					
Procertification R	equested By:	• •	·	Phone		Fax:			
A. PATIENT INFO				1 110116		1 ax			
First Name:	RWATION		Last Name:			DOB:			
			Last Name.	Cit.			ZIP:		
Address:		Mark Dhana		City:		State: Email:	ZIP:		
Home Phone:		Work Phone:			Tau .	Email:			
		kgs Patien	t Height: inches	s orcms	Allergies:				
B. INSURANCE IN			D						
	Aetna Member ID #:			Does patient have other coverage? ☐ Yes ☐ No If yes, provide ID#: Carrier Name:					
Insured:	Group #:			If yes, provide ID#: Carrier Name: Insured:					
	☐ No If yes, provid	de ID #:	1	edicaid: □ Ves	☐ No If yes, prov	/ide ID #:			
C. PRESCRIBER		ue 1D #.	1,414	edicaid.   Tes	□ No II yes, prov	nde ID #.			
First Name:			Last Name:		(Check On	e): 🗌 M.D. 🗌	] D.O. 🗌 N.P. 🗌 P.A		
Address:			I.	City:	·	State:	ZIP:		
Phone:	Fax:		St Lic #:	NPI#:	DEA #:		UPIN:		
Provider Email:			Office Contact Name			Phone:			
	one):  Oncologist	Othor:	Omeo Comac Hame	•		T Hono.			
= -	PROVIDER/ADMINIS		PMATION						
Place of Administ		TRATION INTO	NWATION	Dispensing	Provider/Pharmac	v. Patient Sel	ected choice		
☐ Self-administered ☐ Physician's Office				<u> </u>		Retail Pharmacy			
Outpatient Infusion Center Phone:				-					
	ime:	<u></u>			•				
☐ Home Infusion		none:					·		
Agency N	ame:								
☐ Administration	code(s) (CPT):			_					
Address:				_   TIN:		PIN:			
E. PRODUCT INF	ORMATION								
Request is for:   Dose:	FYARRO (sirolimus	s protein-bound	particles for injectab Frequency:	le suspension) (	albumin-bound)				
F. DIAGNOSIS IN	FORMATION - Pleas	e indicate primar	y ICD code and specif	y any other where	e applicable.				
Primary ICD Code	:		Secondary ICD Co	de:	Other	ICD Code:			
G. CLINICAL INFO	ORMATION - Require	ed clinical informa	ation must be complete	ed in its <u>entirety</u> fo	r all precertification	requests.			
For Initiation Requ	uests (clinical docui	mentation requi	red):						
Malignant perivas	cular epithelioid cel	I tumor (PECom	ıa)						
☐ Yes ☐ No \	Will the requested me	dication be used	as a single agent?						
Please indicate the	ne clinical setting in w	hich the requeste	ed drug will be used: [ ]	☐ Locally advanc ☐ Other	ed unresectable dis	sease 🗌 Meta	astatic disease		
Uterine sarcoma (	•								
Please indicate th	ne clinical setting in w	hich the request	ed drug will be used. [	I Advanced dise	ase I I Recurrent	disease I M	Netastatic disease		

☐ Inoperable disease ☐ Other

☐ Yes ☐ No Will the requested medication be used as a single agent?

☐ Yes ☐ No Is there evidence of unacceptable toxicity or disease progression on the current regimen?

For Continuation Requests (clinical documentation required):



## FYARRO (sirolimus protein-bound particles for injectable suspension) (albumin-bound) Medication Precertification Request

Page 2 of 2

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification Phone: <u>1-866-752-7021</u> (TTY: <u>711</u>)

FAX: <u>1-888-267-3277</u>

For Medicare Advantage Part B: Please Use Medicare Request Form

H. ACKNOWLEDGEMENT			
Request Completed By (Signature Required):	Date: _	1	1
Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent any insurance company by providing materially false information or conceals material information for the purpose of misle insurance act, which is a crime and subjects such person to criminal and civil penalties.			

The plan may request additional information or clarification, if needed, to evaluate requests.